Frontlight ResearchEarly access
CompletedNo phase
Efficacy of ICU-VTE Scale in ICU Patients
Key facts
- Who runs it
- Lijuan Zhang
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 269 people enrolled
- Started
- 1 May 2022
- Ended
- 10 Dec 2023
- Type of study
- Observational
- Record updated
- 8 May 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (6)Hide the full registry criteria
Who can take part
- patients age greater than or equal to 18 years
- Patients or their family members agreed to the study and signed informed consent
Who cannot take part
- Patients admitted to ICU with VTE diagnosis or diagnosed with VTE within 24 hours of admission to ICU
- Use the therapeutic dose of anticoagulation before admission to ICU or within 24 hours in ICU
- Expected ICU stay of less than 48 hours
- Patients cannot obtain imaging data to confirm the presence of VTE during ICU admission
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Venous thromboembolism (VTE) is a common cause of morbidity and mortality among critically ill patients. No uniform standard model of VTE risk for critically ill patients was formatted by now. In 2020, Viarasilpa et al. developed the ICU⁃VTE rating table, mainly for ICU patients. However, it lacks validation. We examined and compared how well the ICU-VTE score predict and stratify VTE risk in comprehensive ICU patients.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy of ICU-VTE Scale in Predicting Venous Thromboembolism in ICU Patients
- Record updated
- 8 May 2024